# TUB-030

Source: https://onco.cc/drugs/tub-030/  
OnCo record `tub-030` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TUB-030 is an experimental antibody-drug conjugate from Tubulis (Gilead), in phase 1 trials for advanced solid tumours, head and neck squamous cell carcinoma and small cell lung cancer and other cancers.

## Summary

TUB-030 is an antibody-drug conjugate from Tubulis (Gilead), with Gilead Sciences as acquirer. An IgG1 antibody against 5T4 joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with P5 conjugation, with a drug-to-antibody ratio of 8. Its furthest stage is phase 1, for advanced solid tumours, head and neck squamous cell carcinoma, small cell lung cancer and non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Tubulis pipeline page: Phase I/IIa study 5-STAR 1-01 (NCT06657222), status shown as Phase 1; recruiting per registry. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: TUB-030
- Modality: Antibody-drug conjugate
- Mechanism: An IgG1 antibody against 5T4 joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with P5 conjugation, with a drug-to-antibody ratio of 8.

## Sources

- Tubulis (Gilead): tubulis.com: https://tubulis.com/our-pipeline/
- Tubulis (Gilead): tubulis.com: https://tubulis.com/our-pipeline/
- Tubulis (Gilead): tubulis.com: https://tubulis.com/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline/
- ClinicalTrials.gov: trials of TUB-030: https://clinicaltrials.gov/search?intr=TUB-030

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Tubulis (Gilead)](https://onco.cc/companies/tubulis/)
- trials: [First in Human Study of TUB-030 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06657222/)

---
JSON: https://onco.cc/api/v1/entities/tub-030.json